"Interferon beta-1b" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A non-glycosylated form of interferon beta-1 that has a serine at position 17. It is used in the treatment of both RELAPSING-REMITTING MULTIPLE SCLEROSIS and CHRONIC PROGRESSIVE MULTIPLE SCLEROSIS.
| Descriptor ID |
D000068576
|
| MeSH Number(s) |
D12.644.276.374.440.890.275.750 D12.776.467.374.440.890.275.750 D23.529.374.440.890.275.750
|
| Concept/Terms |
Interferon beta-1b- Interferon beta-1b
- beta-1b, Interferon
- Beta-IFN-1b
- Interferon Beta, Ser(17)
- Ser(17) IFN-beta
- Serine(17) Interferon Beta
- Interferon beta 1b
- 1b, Interferon beta
- beta 1b, Interferon
- IFN-Beta Ser
- Interferon Beta, Serine(17)
|
Below are MeSH descriptors whose meaning is more general than "Interferon beta-1b".
Below are MeSH descriptors whose meaning is more specific than "Interferon beta-1b".
This graph shows the total number of publications written about "Interferon beta-1b" by people in this website by year, and whether "Interferon beta-1b" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2013 | 0 | 1 | 1 |
| 2016 | 0 | 1 | 1 |
| 2017 | 2 | 1 | 3 |
| 2018 | 1 | 0 | 1 |
| 2020 | 6 | 6 | 12 |
| 2021 | 2 | 0 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Interferon beta-1b" by people in Profiles.
-
Effect of a genetically engineered interferon-alpha versus traditional interferon-alpha in the treatment of moderate-to-severe COVID-19: a randomised clinical trial. Ann Med. 2021 12; 53(1):391-401.
-
Combination of (interferon beta-1b, lopinavir/ritonavir and ribavirin) versus favipiravir in hospitalized patients with non-critical COVID-19: A cohort study. PLoS One. 2021; 16(6):e0252984.
-
Interferon ß-1b for patients with moderate to severe COVID-19 in the inflammatory phase of the disease. J Med Virol. 2021 Jul; 93(7):4102-4107.
-
Baricitinib improves respiratory function in patients treated with corticosteroids for SARS-CoV-2 pneumonia: an observational cohort study. Rheumatology (Oxford). 2021 01 05; 60(1):399-407.
-
Real-world prevalence and consequences of potential drug-drug interactions in the first-wave COVID-19 treatments. J Clin Pharm Ther. 2021 Jun; 46(3):724-730.
-
Randomized controlled open label trial on the use of favipiravir combined with inhaled interferon beta-1b in hospitalized patients with moderate to severe COVID-19 pneumonia. Int J Infect Dis. 2021 Jan; 102:538-543.
-
Early triple antiviral therapy for COVID-19. Lancet. 2020 11 07; 396(10261):1487-1488.
-
Early triple antiviral therapy for COVID-19 - Authors' reply. Lancet. 2020 11 07; 396(10261):1488.
-
Interferon Beta-1b and Lopinavir-Ritonavir for Middle East Respiratory Syndrome. N Engl J Med. 2020 10 22; 383(17):1645-1656.
-
Accelerating Clinical Evaluation of Repurposed Combination Therapies for COVID-19. Am J Trop Med Hyg. 2020 10; 103(4):1364-1366.